One swallow doesn’t make a summer, and I’m not sure if you can count four instances of a product as a trend, but it’s certainly an interesting thread at this year’s CES. At this year’s show, a quartet of companies are showing off urine analysis tools d…
Sennheiser’s Conversation Clear Plus are hearing aids in disguise
It’s taken longer than we’d hope, but since October, the FDA finally established a framework for new category of hearing aids that don’t need a medical exam, prescription or a fitting by an audiologist. Unsurprisingly we’re seeing the first OTC products being announced at CES. Sennheiser, a mainstay of the consumer audio world, is tossing its proverbial hat into the ring with the Conversation Clear Plus.
As the name suggests, the focus appears to be on dialogue (rather than the holistic hearing experience). Sennheiser says the earbuds will make it easier to understand conversations in noisy environments. This, the company claims, is achieved in a number of ways. At the heart of the device is a Sonova chip. Sonova is behind some of the legacy names in hearing aids such as Phonak and Unitron and it also bought Sennheiser’s consumer audio business about 18 months ago.
The Conversation Clear Plus looks a lot like a pair of regular true wireless headphones which will go a long way to removing any stigma or association with conventional hearing aids. Unsurprisingly, they do share a lot of features with regular headphones too. That includes active noise cancellation, even if the application here is more focused on reducing background noise in relation to dialogue.
Sennheiser
Like most wireless headphones you’ll have the option to adjust the amount of noise reduction and there’s a companion app for further tuning your hearing experience. Sennheiser says there are three main prestets: Relax, Communication and Streaming. Those are all fairly self explanatory, but the last one marks a key difference between this category and legacy hearing aids — the ability to stream music and audio from your phone. Some hearing aids can do this, but it’s often a sub-optimal experience given that it’s not what they were primarily designed for. Given Sennheiser’s credentials in the headphone world, it seems likely streaming will be comparable to its consumer headphones.
On a more practical note, the Conversation Clear Plus offers a nine hour battery life per charge, with an additional 27 hours/three charges available via the case.
One of the big promises with OTC hearing aids was a significant reduction in cost. Typically a set with a fitting from an audiologist would cost several thousand dollars, the Conversation Clear Plus will retail for $850. The experiences between the two different product categories will obviously be somewhat distinct, given the different form factor, but the modern, gadgety design will appeal to a lot of folks that might otherwise be turned off by the clinical design of classic hearing aids.
The Conversation Clear Plus will be available for pre-order starting Jan 5 and will go on general sale Jan 20.
研究專家開發可以透過血液偵測阿茲海默症的新技術
現在科學家似乎是研究出了新方法，可以透過血液分析來判斷是否患有阿茲海默症了。
Researchers develop blood test that can reliably detect Alzheimer’s disease
When doctors need to confirm an Alzheimer’s diagnosis, they often turn to a combination of brain imaging and cell analysis. Both have their downsides. The latter involves a lumbar puncture, an invasive and painful procedure that’s more commonly known as a spinal tap. A doctor will insert a needle into the lower back to extract a sample of the patient’s cerebrospinal fluid. A lab technician then tests the sample for signs of progressive nerve cell loss and excessive amyloid and tau protein accumulation. MRI scans are less invasive but they’re often expensive and accessibility is an issue; not every community has access to the technology.
The next best tool for diagnosing Alzheimer’s disease is a blood test. While some can detect abnormal tau protein counts, they’re less effective at spotting the telltale signs of neurodegeneration. But that could soon change. This week, in the journal Brain, a multinational team made up of researchers from Sweden, Italy, the UK and US detailed a new antibody-based blood test they recently developed. The new test can detect brain-derived tau proteins, which are specific to Alzheimer’s disease. Following a study of 600 patients, the team found their test could reliably distinguish the illness from other neurodegenerative diseases.
Dr. Thomas Karikari, a professor of psychiatry at the University of Pittsburgh and one of the co-authors of the study, told The Guardian he hopes the breakthrough could help other researchers design better clinical trials for Alzheimer’s treatments. “A blood test is cheaper, safer and easier to administer, and it can improve clinical confidence in diagnosing Alzheimer’s and selecting participants for clinical trial and disease monitoring,” he said. There’s more work to be done before the test makes its way to your local hospital. To start, the team needs to validate that it works for a wide variety of patients, including those who come from different ethnic backgrounds.